search

Active clinical trials for "Choroidal Neovascularization"

Results 1-10 of 174

VEGFA-targeting Gene Therapy to Treat Retinal and Choroidal Neovascularization Diseases

Neovascular Age-related Macular DegenerationDiabetic Macular Edema1 more

Patients who respond to anti-VEGF therapy but with refractory retinal and choroidal neovascularization diseases including neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion-Macular edema (RVO-ME).

Recruiting20 enrollment criteria

Brolucizumab for CNV Associated With Pathologic Myopia

Pathologic Myopia

The purpose of this study is to determine the effectiveness of antiangiogenic therapy to choroidal neovascularization secondary to pathologic myopia.

Recruiting39 enrollment criteria

Effect of Corona Virus on Intravitreal Injections

Diabetic Macular EdemaAge-Related Macular Degeneration3 more

During pandemic of corona virus, patients compliance may be affected. We aim to study the factors lead to unregulated visits and its implications on the final visual outcome.

Recruiting2 enrollment criteria

Episcleral Brachytherapy for the Treatment of Wet AMD

Macular DegenerationChoroidal Neovascularization

This is a prospective, multi-site, safety and feasibility study of the SalutarisMD SMD-DA system for retrobulbar minimally invasive episcleral brachytherapy device in patients receiving and not responding to anti-VEGF therapy for nAMD. The trial will be open label and non-randomized. The study intervention is a one-time intervention and requires no alteration to the standard of care during the follow-up period.

Active30 enrollment criteria

VISUPRIME® Eye Drops

Macular DegenerationAge Related4 more

The study purpose is to assess the efficacy of VISUPRIME® eye drops in preventing the conjunctival bacterial load in patients undergoing to anti-VEGF injection.

Not yet recruiting24 enrollment criteria

CM082 in Patients With Myopic Choroidal Neovascularization (CNV)

Myopic Choroidal Neovascularisation

This is a Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Intermittent Oral Dosing of CM082 tablets in Chinese Patients With mCNV.

Suspended18 enrollment criteria

Outcomes of Tolerating Subretinal Fluid in Type 1 MNV and PCV

Polypoidal Choroidal VasculopathyChoroidal Neovascularization1 more

The purpose of the present study was to evaluate the outcomes of type 1 macular neovascularization (MNV), including polypoidal choroidal vasculopathy in patients treated tolerating subretinal fluid (SRF) using Aflibercept in a clinical setting. Approximately 150 patients are anticipated to be enrolled in this study. SRF is a primary type of fluid compartment prevalent in type 1 aneurysmal MNV. In a recent study, the prevalence of SRF during 24-month follow-up period was 36.7% to 38.8% in type 1 MNV and polypoidal choroidal vasculopathy (PCV), 20.0% in type 2 MNV, and 7.7% in type 3 MNV. In addition, patients with SRF showed better visual prognosis in type 1 MNV/PCV. For this reason, type 1 MNV is an appropriate candidate for evaluating the influence of tolerating SRF.

Recruiting10 enrollment criteria

Deep Learning OCT and OCTA in NVC

Macular Degeneration Choroidal Neovascularization

To evaluate the activity of neovascular macula degeneretion as assessed by SD-OCTand OCT-A using a split-person study design and deep-learning quantification.

Recruiting9 enrollment criteria

Safety and Preliminary Efficacy Study of WST11 (Stakel®)-Mediated VTP Therapy in Subjects With CNV...

Macular DegenerationChoroidal Neovascularization

The objectives of this study are to evaluate the safety(first objective) and efficacy(second objective)of an experimental drug product,Stakel®, in the treatment of neovascular Age related Macular Degeneration (AMD). The drug product is activated in patients by exposure to light at a specific wavelength ("Vascular Targeted Photodynamic therapy", "VTP"). The exploratory objective is to assess whether it is possible to delay or reduce the requirement for anti Vascular Endothelium Growth Factor (anti VEGF) intravitreal therapy in the first 12 weeks after VTP. All subjects will have a 52 weeks safety follow up telephone call (Not for Adverse Events (AEs) collection).

Terminated28 enrollment criteria

Open-Label, Pilot Study of TG100801 in Patients With Choroidal Neovascularization Due to AMD

Macular DegenerationChoroidal Neovascularization

Wet age-related macular degeneration (AMD) is caused by the formation and growth of abnormal blood vessels (angiogenesis) in the retina. The new blood vessels have fragile walls and can leak fluid into the retina. The build-up of fluid (edema) under the macula can distort vision or cause vision loss. TG100801 is a topical (eye drop) therapy that has been shown to inhibit ocular angiogenesis, vascular leak, and inflammation in laboratory studies. The primary purpose of this pilot study is to evaluate the ability of topical administration of TG100801 to reduce the amount of fluid in the retina in patients with AMD following 30 days of treatment. An additional objective is to evaluate the safety of TG100801 in patients with AMD.

Terminated17 enrollment criteria
12...18

Need Help? Contact our team!


We'll reach out to this number within 24 hrs